Last updated: 10/23/2020 08:30:04

Airflow Limitation in Cardiac Diseases in EuropeALICE

GSK study ID
115398
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Airflow Limitation in Cardiac Diseases in Europe
Trial description: This is a cross-sectional, observational study, investigating the point prevalence of Airflow Limitation in current or former smokers with established ischemic heart disease. The study will recruit up to 3000 patients from cardiology clinics at hospitals across Europe.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

Prevalence of Airflow Limitation

Timeframe: 1 day

Secondary outcomes:

Severity of AL

Timeframe: 1 day

prevalence of restrictive AL

Timeframe: 1 day

Prevalence of AL

Timeframe: 1 day

Presence of past history of AL/COPD

Timeframe: 1 day

COPD Assessment testâ„¢ (CAT)

Timeframe: 1 day

Short Form 12 (SF12)

Timeframe: 1 day

Cardiac Health Profile (CHP)

Timeframe: 1 day

Healthcare resource utilisation

Timeframe: within previous 12 months

Interventions:
  • Procedure/surgery: Spirometry
  • Enrollment:
    3000
    Primary completion date:
    2012-29-06
    Observational study model:
    Case-Only
    Time perspective:
    Cross-Sectional
    Clinical publications:
    Not applicable
    Medical condition
    Pulmonary Disease, Chronic Obstructive
    Product
    Not applicable
    Collaborators
    Not applicable
    Study date(s)
    October 2011 to June 2012
    Type
    Observational
    Phase
    Not applicable

    Participation criteria

    Sex
    Female & Male
    Age
    40+ years
    Accepts healthy volunteers
    No
    • Subjects aged ≥40 years;
    • Current or former smokers with ≥10 pack years;
    • Subjects for whom spirometry is contraindicated;
    • Subjects with recent surgery or MI (within 1 month); lower respiratory tract infection or pneumothorax (within 2 months); or stroke (within 12 months);

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    GSK Investigational Site
    AMERSFOORT, Netherlands, 3818 ES
    Status
    Study Complete
    Location
    GSK Investigational Site
    Berlin, Berlin, Germany, 13347
    Status
    Study Complete
    Location
    GSK Investigational Site
    Dublin, Ireland, 4
    Status
    Study Complete
    Location
    GSK Investigational Site
    Dublin, Ireland, 9
    Status
    Study Complete
    Location
    GSK Investigational Site
    Gent, Belgium, 9000
    Status
    Study Complete
    Location
    GSK Investigational Site
    LUND, Sweden, SE-222 21
    Status
    Study Complete
    Showing 1 - 6 of 15 Results

    Study documents

    Protocol
    Available language(s): English
    Scientific result summary
    Available language(s): English

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Refer to study documents

    Recruitment status
    Study complete
    Actual primary completion date
    2012-29-06
    Actual study completion date
    2012-29-06

    Plain language summaries

    Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

    Additional information about the trial

    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website